Risk of Hepatocellular Cancer in U.S. Patients With Compensated Cirrhosis Treated With Direct‐Acting Antivirals Versus Interferon
The study shows a reduced risk of de novo HCC among patients with chronic HCV-related compensated cirrhosis who received DAA treatment compared to that of untreated patients. There were no differences in HCC risk between DAA-treated and IFN-treated patients.
Authors
- Hashem B. El‐Serag (ORCID: https://orcid.org/0000-0001-5964-7579)
- Michelle Luster
- Hao T. Duong
- Lois Larsen
- Lani R. Wegrzyn
- Deanna Hill
- Barbara Haber (ORCID: https://orcid.org/0000-0001-6315-5470)
- John Marcinak
- Fasiha Kanwal (ORCID: https://orcid.org/0000-0001-6715-3966)
- Cándido Hernández
- Margaret Burroughs
Institutions
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- Michael E. DeBakey VA Medical Center (US)
- Baylor College of Medicine (US)
- AbbVie (United States) (US)
- Center for Innovation (US)
- Gilead Sciences (United States) (US)
Publication Details
- Journal
- Alimentary Pharmacology & Therapeutics
- Published
- 2025-02-07
- DOI
- https://doi.org/10.1111/apt.18525
- Citations
- 4
- Primary Topic
- Hepatitis C virus research
- Type
- article
- Field-Weighted Citation Impact
- 5.29
Funders
- Cancer Prevention and Research Institute of Texas
- National Institute of Diabetes and Digestive and Kidney Diseases